British global healthcare company GSK has launched its new legal entity in Viet Nam – GSK Pharma Viet Nam Company Limited (GSK Vietnam) – with an investment capital of US$200 million.
For over nearly three decades, GSK’s representative office in Viet Nam has contributed to preventing and treating diseases in the country with its vaccines and medicines.
The company said in a press release that it aims to deliver positive impacts on healthcare quality on more than one third of the Vietnamese population in the next three years.
On May 11, it announced the establishment of GSK Vietnam to continue operating and growing sustainably and responsibly in the country.
It targets becoming “one of the most innovative, best performing, and trusted healthcare companies,” it said.
Outlining the healthcare trends and the role of GSK Vietnam in its partnerships with the medical sector, Nguyen Thanh Lam, deputy director of the Drug Administration of Viet Nam, said GSK Vietnam is expected to continue to bring effective solutions from prevention to treatment, following disease patterns in the country.
Pham Thi My Lien, President of GSK Pharma Vietnam Company Limited, said the company was committed to continue working together with its healthcare partners in solving health-related challenges and cooperating in delivering long-term healthcare benefits to the Vietnamese people.
“We aim to protect six out of ten newborn babies from life-threatening vaccine-preventable diseases and hundreds of thousands of adults and groups with underlining conditions,” Lien said.
She said the company will also provide treatment for millions of asthma and chronic obstructive pulmonary disease patients, and make available effective and quality antibiotics for tens of millions of community-acquired respiratory tract infection patients.
The company marked the occasion of its establishment by singing Memoranda of Understanding (MoUs) with the Viet Nam Medical Association, National Phytopharma Joint-Stock Company (Phytopharma) and Vietnam Vaccine Company (VNVC).
The signatories will cooperate in providing continuous medical education to enhance the quality of treatment and clinical practice for healthcare professionals across the country.
They are also committed to learn, exchange and share experiences in life-course immunisation programmes in the region and from countries around the world to move towards proactive public health care.
A sustainable pharmaceutical supply chain will be established to help more Vietnamese people access effective prevention and treatment options.
Under the MoUs, the parties will also strengthen knowledge exchange, expand immunisation coverage to children and adults in the country and enhance disease awareness among public with necessary knowledge. — VNS